Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
The combination works by decreasing hunger and increasing the feeling of fullness. The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema ...
Denmark-headquartered Novo Nordisk, a leading global healthcare company founded in 1923 to drive change to defeat serious chronic diseases built upon our heritage in diabetes, announced headline ...
Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial ...
Amitabh Bachchan’s character to play a more significant role in the sequel. The megastar will return to the sets in May to ...
Viyaara Realty, a premier Mumbai-based real estate developer, dedicated to creating exceptional living spaces is set to ...
3d
Zacks.com on MSNNVO Stock Down 9% as CagriSema Misses Target in Second Obesity StudyNovo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...
4d
GlobalData on MSNNovo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trialThe Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
The story follows Ne Zha, a rebellious boy-god, and his dragon ally, Ao Bing, who, after surviving a celestial catastrophe, ...
One report claims it will run on iOS 18, allowing the iPhone 17 Pro Max to leverage Apple Intelligence, an advanced AI-driven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results